Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Reker

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
Planta Medica|February 27, 2015
Chemography of natural product spaceTomoyuki Miyao, Daniel Reker, Petra Schneider, et al.
Nature Reviews. Drug Discovery|April 2, 2024
The landscape of small-molecule prodrugsZachary Fralish, Ashley Chen, Shaharyar Khan, et al.
Pharmaceutical Research|October 30, 2020
Historical Evolution and Provider Awareness of Inactive Ingredients in Oral MedicationsDaniel Reker, Steven M Blum, Peter Wade, et al.
Journal of Computer-Aided Molecular Design|May 30, 2020
Artificial intelligence in chemistry and drug designNathan Brown, Peter Ertl, Richard Lewis, et al.
Angewandte Chemie (International Ed. in English)|September 9, 2016
Deorphaning the Macromolecular Targets of the Natural Anticancer Compound DoliculideGisbert Schneider, Daniel Reker, Tao Chen, et al.
Trends in Molecular Medicine|September 24, 2013
Common non-epigenetic drugs as epigenetic modulatorsJörn Lötsch, Gisbert Schneider, Daniel Reker, et al.
Journal of Immunological Methods|September 24, 2013
Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomabNikolai Siebert, Diana Seidel, Christin Eger, et al.
Molecular Informatics|August 20, 2013
Chemically Advanced Template Search (CATS) for Scaffold-Hopping and Prospective Target Prediction for 'Orphan' MoleculesMichael Reutlinger, Christian P Koch, Daniel Reker, et al.
Angewandte Chemie (International Ed. in English)|December 6, 2014
Multidimensional de novo design reveals 5-HT2B receptor-selective ligandsTiago Rodrigues, Nadine Hauser, Daniel Reker, et al.
Nature Computational Science|February 27, 2024
Characterizing emerging companies in computational drug developmentChloe Markey, Samuel Croset, Olivia Ruth Woolley, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Planta Medica|February 27, 2015
Chemography of natural product spaceTomoyuki Miyao, Daniel Reker, Petra Schneider, et al.
Nature Reviews. Drug Discovery|April 2, 2024
The landscape of small-molecule prodrugsZachary Fralish, Ashley Chen, Shaharyar Khan, et al.
Pharmaceutical Research|October 30, 2020
Historical Evolution and Provider Awareness of Inactive Ingredients in Oral MedicationsDaniel Reker, Steven M Blum, Peter Wade, et al.
Journal of Computer-Aided Molecular Design|May 30, 2020
Artificial intelligence in chemistry and drug designNathan Brown, Peter Ertl, Richard Lewis, et al.
Angewandte Chemie (International Ed. in English)|September 9, 2016
Deorphaning the Macromolecular Targets of the Natural Anticancer Compound DoliculideGisbert Schneider, Daniel Reker, Tao Chen, et al.
Trends in Molecular Medicine|September 24, 2013
Common non-epigenetic drugs as epigenetic modulatorsJörn Lötsch, Gisbert Schneider, Daniel Reker, et al.
Journal of Immunological Methods|September 24, 2013
Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomabNikolai Siebert, Diana Seidel, Christin Eger, et al.
Molecular Informatics|August 20, 2013
Chemically Advanced Template Search (CATS) for Scaffold-Hopping and Prospective Target Prediction for 'Orphan' MoleculesMichael Reutlinger, Christian P Koch, Daniel Reker, et al.
Angewandte Chemie (International Ed. in English)|December 6, 2014
Multidimensional de novo design reveals 5-HT2B receptor-selective ligandsTiago Rodrigues, Nadine Hauser, Daniel Reker, et al.
Nature Computational Science|February 27, 2024
Characterizing emerging companies in computational drug developmentChloe Markey, Samuel Croset, Olivia Ruth Woolley, et al.
Pageof 6